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Abstract
Introduction: Rheumatoid arthritis (RA) is a systemic disease manifested by chronic inflammation in multiple articular 
joints, including the knees and small joints of the hands and feet. We have developed a unique modification to a 
clinically accepted method for delivering therapies directly to the synovium. Our therapy is based on our previous 
discovery of an analog peptide (A9) with amino acid substitutions made at positions 260 (I to A), 261 (A to B), and 263 
(F to N) that could profoundly suppress immunity to type II collagen (CII) and arthritis in the collagen-induced arthritis 
model (CIA).
Methods: We engineered an adenoviral vector to contain the CB11 portion of recombinant type II collagen and used 
PCR to introduce point mutations at three sites within (CII124-402, 260A, 261B, 263D), (rCB11-A9) so that the resulting molecule 
contained the A9 sequence at the exact site of the wild-type sequence.
Results: We used this construct to target intra-articular tissues of mice and utilized the collagen-induced arthritis 
model to show that this treatment strategy provided a sustained, local therapy for individual arthritic joints, effective 
whether given to prevent arthritis or as a treatment. We also developed a novel system for in vivo bioimaging, using the 
firefly luciferase reporter gene to allow serial bioluminescence imaging to show that luciferase can be detected as late 
as 18 days post injection into the joint.
Conclusions: Our therapy is unique in that we target synovial cells to ultimately shut down T cell-mediated 
inflammation. Its effectiveness is based on its ability to transform potential inflammatory T cells and/or bystander T 
cells into therapeutic (regulatory-like) T cells which secrete interleukin (IL)-4. We believe this approach has potential to 
effectively suppress RA with minimal side effects.
Introduction
Rheumatoid arthritis (RA) is a systemic disease with pol-
yarticular manifestation of chronic inflammation in mul-
tiple articular joints, including the knees and small joints
of the hands and feet. The current systemic anti-TNF-α
therapies ameliorate disease in 60% to 70% of RA patients
[1]. However, biologics must be given systemically in rela-
tively high dosages to achieve constant therapeutic levels
in the joints, and significant side effects have been
reported [2].
Gene therapy may provide an effective alternative to
drug delivery for the treatment of arthritis [3]. Although
various strategies have been tested, those that target gene
delivery to the synovial lining of joints have made the
most experimental progress [3,4]. This strategy has
shown efficacy in several experimental models of RA [5-
7]. For this reason, we have developed a unique modifica-
tion to a clinically acceptable method of gene delivery to
allow delivery of the gene product directly to the syn-
ovium. Our therapy is based on our previous discovery of
an analog peptide (A9) of type II collagen (CII) with
amino acid substitutions made at positions 260 (I to A),
261 (A to B), and 263 (F to N) that could profoundly sup-
press immunity to CII and arthritis in the collagen-
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Page 2 of 9induced arthritis (CIA) model [8]. Such collagen peptides
containing specially designed substitutions and expressed
as a gene products may provide an ideal choice to be
delivered to the joints.
We engineered an adenoviral gene-based therapy and
showed that this treatment strategy provided a sustained,
local therapy for individual arthritic joints. Our therapy is
unique in that we target synovial cells to ultimately shut
down T cell-mediated inflammation. Its effectiveness is
based on its ability to transform potential inflammatory T
cells and/or bystander T cells into therapeutic (regula-
tory-like) T cells [8]. They are potentially safer than cur-
rent therapies because they contain a modification of an
endogenous naturally occurring protein, used to inter-
rupt the autoimmune T cell attack and allow for tissue
repair. We believe this approach has the potential to
become applicable for treatment of RA.
Materials and methods
Preparation of tissue-derived type II collagen
Native CII was solubilized from fetal calf articular carti-
lage by limited pepsin-digestion and purified as described
earlier [9]. The purified collagen was dissolved in cold
0.01 M acetic acid at 4 mg/ml and stored frozen at -70°C
until used.
Animals
DBA/1 mice were obtained from the Jackson Laborato-
ries and raised in our animal facility. They were fed stan-
dard rodent chow (Ralston Purina Co., St. Louis, MO,
USA) and water ad libitum. The environment was spe-
cific pathogen-free and sentinel mice were tested rou-
tinely for mouse hepatitis and Sendai viruses. All animals
were kept until the age of 7 to 10 weeks before being used
for experiments, which were conducted in accordance
with approved Institutional Animal Care and Use Com-
mittee (IACUC) protocols.
Immunization
CII was solubilized in 0.01 M acetic acid at a concentra-
tion of 4 mg/ml and emulsified with an equal volume of
complete Freund's adjuvant (CFA) containing 4 mg/ml of
Mycobacterium tuberculosis strain H37Ra (Difco Micro-
biology Products, Becton Dickinson, NJ, USA) [10]. Each
mouse received 100 μg of CII emulsified in CFA intrader-
mally at the base of the tail.
Generation of replication-defective, recombinant 
adenoviral vector expressing modified CB11
Recombinant adenovirus carrying cDNA for rCB11-A9
was generated using a BD Adeno-X Expression System
(BD Biosciences Clontech (San Jose, California, USA)),
which incorporates the rCB11-A9 expression cassette
into a replication-incompetent (ΔE1/ΔE3) human adeno-
viral type 5 (Ad5) genome. All work was conducted in
accordance with approved Institutional Biosafety Com-
mittee (IBC) protocols. In brief, an 834 bp of full-length
murine CB11 gene was PCR-amplified from murine
spleen cDNA and cloned into the PCR2 vector (Invitro-
gen, Carlsbad, California, USA). We introduced three
point mutations (I260A, A261B, and F263N) within the
immunodominant T cell determinant of CB11 (CII124-402)
to generate an rCB11-A9 construct. The rCB11-A9
cDNA was then excised with BamHI/EcoR I and sub-
cloned into the same sites of the pShuttle2 vector to con-
struct an rCB11-A9 specific expression cassette. For in
vivo bioimaging analysis, a cDNA encoding the luciferase
gene was also subcloned into the pShuttle2 to establish
the Adeno-X-luciferase expression cassette. To produce
recombinant adenoviral DNA containing rCB11-A9 or
luciferase, we excised the expression cassettes from
recombinant pShuttle2 plasmid DNA by digesting with I-
Ceu I and PI-Sce I and ligated the expression cassettes
with prelinearized BD Adeno-X Viral DNA (I-Ceu I and
PI-Sce I digested). Low passage HEK293 cells were trans-
fected with the resultant recombinant adenoviral DNA
using the calcium phosphate method [11]. The recombi-
nant adenoviral particles were harvested by lysing trans-
fected cells. The resultant AdenoX-rCB11-A9 is a
replication-incompetent recombinant adenovirus. High
titer viral stocks (about 108 to 109 plaque forming units
(pfu)/ml) were obtained by amplifying recombinant ade-
novirus in HEK 293 cells. A construct (pShuttle2-lacZ)
was included in the BD Adeno-X Expression System and
recombinant AdenoX-lacZ was generated as described
above and used as a control. The recombinant adenoviral
titers were determined by BD Adeno-X Rapid Titer Kit
[11,12].
Production and purification of recombinant CB11 and 
CB11-A9
In some experiments, a baculoviral expression system
was used to produce rCB11 (CII124-402bac) in insect cells
essentially as described earlier [13]. The cDNA for both
recombinant CB11 and CB11-A9 (rCB11 and rCB11-A9)
were subcloned into a Gateway entry vector (Invitrogen,
Carlsbad, California, USA) and validated. The resultant
Gateway entry vectors containing either rCB11 or rCB11-
A9 were ligated with BaculoDirect Linear DNA (Invitro-
gen, Carlsbad, California, USA) and transfected into Sf9
insect cells. Supernatants from lysed insect cells were col-
lected and screened for expression by performing SDS-
PAGE and western blot analysis. After validated, high
titers of recombinant baculovirus were obtained by re-
infecting Sf9 cells twice and supernatants collected from
lysed cells. To express the recombinant proteins Hi5 cells
was infected with high titer of baculovirus. Supernatants
from cultured Hi5 cells were harvested by centrifugation
and the recombinant proteins purified by gel filtration
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dilute acetic acid.
Synovial injections
The hind ankle joints of DBA/1 mice were injected intra-
articularly with 10 ul of adenoviral vector 1 × 107 pfu of
adenovirus, containing the DNA for either luciferase,
rCB11-A9, or Lac-Z. In some experiments, selected mice
were injected intraperitoneally with luciferin, and the
expression of the transgene (luciferase) was detected by
bioluminescent imaging using a liquid nitrogen cooled
CCD camera (Photometric Chemipro, Roper Scientific,
NJ, USA) mounted on a dark box one hour later. Images
were acquired and analyzed using Metamorph software
(Universal Imaging Co., Dowlington, PA, USA).
Measurement of the incidence and severity of arthritis
The incidence and severity of arthritis were determined
by visually examining each forepaw and hindpaw and
scoring them on a scale of 0 to 4 as described previously
[10]. Scoring was conducted by two examiners, one of
whom was unaware of the identity of the treatment
groups. Each mouse was scored thrice weekly beginning
three weeks post immunization and continuing for eight
weeks. The incidence of arthritis (number of animals
with one or more arthritic limbs) and mean severity score
(sum of the severity scores/total number of animals in the
group) was recorded at each time point.
In a prevention protocol, four groups of 10 DBA/1 mice
each were administered intra-articularly in the ankles,
either adenoX-rCB11-A9 or adenoX-LacZ. The mice
were immunized with CII/CFA either three or seven days
after the injection.
In a treatment protocol, groups of three DBA/1 mice
were immunized with CII/CFA and at the time arthritis
reached a severity score of two or greater, the mice were
administered intra-articularly in the hind ankles either
adenoX-rCB11-A9 or adenoX-LacZ.
Measurement of serum antibody titers
Mice were bled at six weeks after immunization and sera
were analyzed for antibodies reactive with native CII
using a modification of an ELISA previously described
[10]. Serial dilutions of a standard serum were added to
each plate. From these values, a standard curve was
derived by computer analysis using a four-parameter
logistic curve. Results are reported as units of activity,
derived by comparison of test sera with the curve derived
from the standard serum which was arbitrarily defined as
having 50 units of activity. Reactivity to CII was not
detected in sera obtained from normal mice.
Measurement of cytokines
Groups of three DBA/1 mice were administered intra-
articularly either adenoX-rCB11-A9 or adenoX-LacZ and
the mice were immunized with CII/CFA three days after
the injection. Draining lymph node cells were harvested
14 days after the immunization and cultured (5 × 106
cells/ml) with 100 μg/ml of either the mouse collagen
immunodominant peptide, Ova (negative control), or
purified protein derivative (PPD) (positive control).
Supernatants were collected 72 hours later and analyzed
for the presence of multiple cytokines (IL-4, IL-5, IL-10,
IL-2, interferon (IFN)γ, and IL-17 by a Bio-plex mouse
cytokine assay (Bio-Rad, Hercules, CA, USA) according
to the manufacturer's protocol. Values are expressed as
picograms per ml and represent the mean values for each
group.
Statistical analysis
The incidence of arthritis in various groups of mice was
compared using Fisher's Exact Test. Mean severity scores
and antibody levels were compared using Student's t test.
Results
An adenoviral construct efficiently transfers an exogene 
into arthritic synovial tissues in collagen-induced arthritis
Using a replication-defective, recombinant adenovirus,
we incorporated the cDNA for lac-Z, and assessed the
transfection efficiency of the recombinant adenovirus
delivered into arthritic ankles of DBA/1 mice previously
immunized with CII/CFA. Each hind ankle was injected
intra-articularly with 107 pfu of the adenoviral particles.
Forty-eight hours later, the animals were sacrificed and
histology was performed on the involved joints. As
shown in Figure 1, staining with β-galactosidase clearly
demonstrated that the adenovirus-expressed gene prod-
uct was present in synovial cells, lining the surface of the
synovium near the cartilage surface (Figure 1). Although
most of the transfected cells are fibroblast-like synovio-
cytes, a smaller number of monocyte-like synovial cells
were also transfected. These data confirm that arthritic
synovial cells can be readily transfected with adenoviral
constructs and that an adenovirus carrying gene can be
efficiently expressed.
Development of the baculovirus construct for modified 
collagen (rCB11-A9) expression and evaluation of its 
immunogenicity
To develop a unique collagen-based therapy, we built
upon our previous work demonstrating that a synthetic
peptide of CII, which contained three amino acid substi-
tutions (A9), could effectively suppress arthritis. We used
PCR to introduce three point mutations within the CB11
portion of recombinant type II collagen (CII124-402,260A,
261B, 263D), (rCB11-A9) so that the resulting molecule con-
tained the A9 sequence at the exact site of the wild-type
sequence. To test for safety, we developed a baculovirus
construct and expressed the rCB11-A9 protein in droso-
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tion of lysine hydroxylase and hydroxylysine
glycosyltransferase, allowing partial glycosylation of the
product. This system closely mimics the post-transla-
tional system of mammalian cells. The baculovirus-
expressed collagen was purified, emulsified with CFA,
and used to immunize DBA/1 mice to observe for the
development of arthritis. We found that rCB11-A9 was
unable to induce either arthritis or antibodies to CII
(Table 1). On the other hand, the unmodified control
rCB11-induced arthritis at its expected incidence of 40%
as well as inducing a significant antibody response to
murine CII (Table 1). These data suggest that rCB11-A9
will be safer than many conventional therapies, if used to
treat arthritis because it is non-immunogenic and non-
arthritogenic.
Development of a method for in vivo bioimaging to track 
the duration of gene expression
Noninvasive bioimaging is an exciting new development
that can be applied to clinical diseases to monitor the
duration of gene expression and determine the extent of
the therapeutic effect. As adenoviral constructs typically
can be transcribed but not replicated with cell division, it
was important to predict the length of time the intro-
duced therapy might be effective. We developed a system
for in vivo bioimaging in which the firefly luciferase
reporter gene was incorporated into our adenoviral vec-
tor and this construct was injected into murine ankle
joints. Serial bioluminescence imaging of gene expression
was performed on days 1, 3, 12 and 18 following intrap-
eritoneal injection of luciferin, the substrate of luciferase.
As shown in Figure 2, the injected sites of joints clearly
showed the expression of luciferase, as indicated by the
green luminescent color and the expression of luciferase
could be detected as late as 18 days post injection. By day
21 the green color was no longer detectable. Taken
together, these data confirm that a transgene carried by
the adenoviral vector gene can be efficiently transferred
into the joints and a sustained release of expression can
be successfully achieved.
Evaluation of the potency of the AdenoX-rCB11-A9 
construct in suppression of CIA
All the previous data suggest that local expression of
rCB11-A9 in arthritic joints will be able to effectively
modulate CIA. To test this hypothesis the rCB11-A9 was
incorporated into the adenoviral genome and the result-
ing construct (AdenoX-rCB11A9) tested. To evaluate
potency in the treatment of arthritis, DBA/1 mice were
injected intra-articularly (in the hind ankles) with the
adenoX-rCB11-A9 either three or seven days prior to
immunization with CII/CFA and were observed for the
development of arthritis. Control mice were injected with
adenoX-lacZ. As predicted, the mice treated with the
adenoX-rCB11-A9 demonstrated a significant decrease
in the severity of arthritis as manifested by the severity
scores and visual inspection (Figure 3, panels a and b).
The control adenoX-Lac-Z construct had no effect. Con-
cordant with a decrease in the incidence and severity of
arthritis, antibody production to CII was significantly
decreased (Table 2). The hindpaws injected with Ade-
noX-rCB11A9 were profoundly affected when compared
with adenoX-lacZ injected control hindpaws, (severity
scores of 0 vs 2.8 ± 2.7, P ≤ 0.025 if injected three days
prior to immunization and 0 vs 2.2 ± 1.8, P ≤ 0.01 if
injected seven days prior to immunization). The non-
injected forepaws developed arthritis with attenuated
Figure 1 Localization of adenovirus-expressed recombinant pro-
tein in arthritic mouse paws. Two DBA/1 mice were immunized with 
type II collagen/complete Freund's adjuvant and one week later inject-
ed intra-articularly (into hind ankles) with 10 μl containing 10× 7 total 
plaque forming units adenoviral particles encoding Lac-Z. The animals 
were sacrificed 48 hours later and the tissues photographed using a re-
verse phase microscope (50×). In the upper panel, the tissues were in-
cubated with beta galactosidase substrate. The majority of the cells 
containing Lac-Z (upper panel, stained blue) appear to be fibroblast-
like synoviocytes lining the surface of the synovium, although staining 
can also be detected in monocyte-like synoviocytes. The uninjected 
hindpaws were used as controls for each animal (lower panel). The 
data shown are representative of data obtained by analyzing multiple 
sections of each hindpaw.
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when treated three days prior, to imunization or 1.8 ± 2 vs
4.8 ± 1.5, P ≤ 0.01 when treated seven days prior to
immunization). These data indicate that therapy with
adenoX-rCB11-A9 significantly down regulated the
immune responses to CII in vivo and attenuated the
development of arthritis.
Mechanism of suppression
We have reported that a major component of the mecha-
nism of action for the synthetic peptide analog A9 is its
ability to cause T cells to secrete a suppressive cytokine
profile. Its effectiveness is based on its ability to trans-
form potential inflammatory T cells and/or bystander T
cells into therapeutic (regulatory-like) T cells [8,14].
Table 1: A9-modified recombinant CB11 is not arthritogenic
Format of collagenous immunogena Incidenceb Antibodies to CIIc
rCB11-A9/CFA 0/5 (0%) 2.5 ± 1, P < 0.05
rCB11/CFA 2/5 (40%) 21.3 ± 5
a. The baculovirus-expressed products, both rCB11 (recombinant CII124-402)) and rCB11-A9 (recombinant CII124-402,260A, 261B, 263D) were 
collected, emulsified with complete Freund's adjuvant (CFA), and used to immunize groups of five DBA/1 mice to observe for the 
development of arthritis. We found that modified rCB11-A9 was unable to induce either arthritis or significant antibody titers to type II 
collagen (CII) while the control unmodified rCB11-induced arthritis at its expected incidence of 40% as well as inducing a greater antibody 
response to murine CII.
b. Incidence is reported at six weeks following immunization.
c. Antibody levels were measured by ELISA and reported as arbitrary units based on comparison to a standard antiserum run simultaneously.
Figure 2 Adenoviral-mediated gene transfer in joints of live mice. 
Two mice were injected with 10 μl of adenoviral particles (1 × 107 
plaque forming units) expressing luciferase into each of the hind ankle 
joints. At various time points, the mice were injected intraperitoneally 
with luciferin, and expression of the transgene (luciferase) detected by 
bioluminescent imaging at one hour after administration of luciferin. 
The injected joints clearly showed the expression of luciferase, as indi-
cated by the green luminescent color and the expression of luciferase 
could be detected as late as 18 days post injection.
 























Table 2: AdenoX-rCB11-A9 treatment suppresses anti-CII 
antibodies
Antibodies to CII in treated mice
Treatmenta Antibodies to CIIb
AdenoX-rCB11-A9 (imm CII/
CFA 3 days later)
19.6 ± 2, P < 0.05
AdenoX-rCB11-A9 (imm CII/
CFA 7 days later)
16.2 ± 2 P < 0.005
AdenoX-lacZ (imm CII/CFA 3 
days later)
37.2 ± 10
AdenoX-lacZ (imm CII/CFA 7 
days later)
45.0 ± 9
a. Four groups of 10 DBA/1 mice each were administered intra-
articularly either adenoX-rCB11-A9 (adenoviral construct with 
DNA encoding (CII124-402,260A, 261B, 263D) or adenoX-LacZ 
(adenoviral construct with DNA encoding LacZ). The mice were 
immunized with type II collagen/complete Freund's adjuvant 
(CII/CFA) either three or seven days after the injection and sera 
was collected six weeks after the immunization to test for 
antibodies to CII. As noted the adenoX-rCB11-A9 was extremely 
effective at suppressing the development of antibodies to CII, 
irregardless of whether the mice were immunized three days or 
seven days later.
b. Antibody levels were measured by ELISA and reported as 
arbitrary units based on comparison to a standard antiserum run 
simultaneously.
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antigen-specific T cells found in draining lymph nodes
can accurately reflect the T cell responses of arthritic
joints [15], we examined the secretion of a panel of cytok-
ines IFN-γ and IL-2 (Th1), IL-10 and IL-4 (Th2) and IL-
17 (Th17), by testing supernatants from draining lymph
node cells of mice cultured with the murine immu-
nodominant determinant. We found that following treat-
ment with adenoX-CB11-A9, the Th1 and Th17 cytokine
responses to murine CII were significantly decreased
compared with those induced following treatment with
adenoX-lacZ. Similarly, the Th2 cytokines IL-5 and IL-10
were decreased. On the other hand, treatment with the
adenoX-rCB11-A9 induced a significantly greater IL-4
response to murine CII when compared with the lac-Z
control (Table 3). These data are consistent with the con-
cept that IL-4 has a unique role in the suppression of
arthritis that is only partially duplicated by other Th2-
type cytokines in the absence of IL-4 [16]. Taken together
these data suggest that the adenoX-rCB11-A9 therapy
may work by inducing a population of T cells to redirect
their cytokine response to secrete predominantly IL-4, a
cytokine known to ameliorate arthritis. The ability to
induce a population of regulatory-like T cells to secrete
suppressive cytokines in the presence of murine CII as
well as the ability to redirect inflammatory cells toward a
more suppressive phenotype may explain the profound
downregulatory effects adenoX-rCB11-A9 has on CIA.
Potency of AdenoX-rCB11-A9 in suppression of CIA when 
injected after the onset of arthritis
In clinical situations, gene therapy is more likely to be
used therapeutically rather than to prevent disease. To
determine the effectiveness of this treatment on well-
established arthritis, we immunized mice with CII/CFA
and at the onset of arthritis (severity score greater than
two), we introduced the adenoX-rCB11-A9 into the
joints. As shown in Figure 3, the mice injected with the
adenoX-rCB11-A9 had a reversal of arthritis, reaching
severity scores of 0 within five days and the modulation of
arthritis lasted approximately three weeks after the injec-
tion. Control mice injected with the adenoX-lacZ control
did not improve and progressed to develop a more severe
arthritis (Figure 4). The time course for the modulation of
arthritis fits quite accurately with the time course pre-
dicted by the bioimaging data.
Discussion
Our aim was to engineer an adenoviral-based therapy
designed to make synovial cells secrete a modified natu-
rally produced molecule, type II collagen, thereby provid-
ing a sustained, local therapy for individual arthritic
joints. This approach is attractive because joints are dis-
crete, accessible cavities that can be readily injected.
Many different genes have been evaluated for their ability
to treat animal models of RA [17]. These have led to sev-
eral clinical trials, confirming the feasibility and in a pre-
liminary fashion, safety of gene transfer to human
arthritic joints [3,4,18,19].
Recently, several studies using adenoviral-mediated
gene transfer of therapeutic genes for animal model treat-
ment have been reported [7,20-22]. Adenoviruses carry
their genetic material in the form of double-stranded
Figure 3 Treatment with adenoX-rCB11-A9 can prevent CIA. (a) 
Groups of 10 DBA/1 mice were administered intra-articularly either ad-
enoX-rCB11-A9 (square, circle) or adenoX-LacZ (triangle, diamond). 
The mice were immunized with type II collagen/complete Freund's 
adjuvant either three (square, triangle) or seven (circle, diamond) days 
after the injection and all mice were observed for the development of 
arthritis. The data points reflect the mean severity score (sum of the se-
verity scores/total number of animals in the group) at each time point. 
As shown the adenoX-rCB11-A9 was extremely effective at preventing 
the development of arthritis, whether the mice were immunized three 
days prior to immunization (final severity scores 1.3 ± 1.5 vs 6.8 ± 5.3, P 
≤ 0.025) or seven days prior to immunization (final severity scores 1.8 ± 
2.0 vs 7.0 ± 2.5, P ≤ 0.005). The final incidence of arthritis was (square = 
20%, triangle = 90%, P ≤ 0.003) and (circle = 20%, diamond= 100%, P ≤ 
0.0004). (b) Photographs of an arthritic hind paw from a DBA/1 mouse 
injected with adenoX-lacZ (left panel) and a hind paw from a DBA/1 
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molecule is left free in the nucleus of the host cell, and is
transcribed, but not replicated. The advantages of this
therapy are two-fold [23]. The treatment gives a sustained
release of the material directly into the joint cavity,
greatly decreasing the amount of material required and
the number of injections necessary. Second, the absence
of integration into the host cell's genome lessens the pos-
sibility of permanent side effects, and prevents the possi-
bility of malignant-type transformations. Although
concerns about the safety of adenovirus vectors have
been raised, newer genetically crippled versions of the
virus together with modified or deleted capsid sequences
have demonstrated an increased safety and potential for
stable transgene expression [23].
Most gene transfer strategies for treatment of RA are
currently broad based, designed for introducing cytok-
ines [3,4,18-22]. The capability of collagen peptides to act
locally to induce T cells to secrete suppressive cytokines
in a limited environment makes them interesting as
potential therapeutic reagents in suppressing RA. Our
therapy is based on our previous discovery of an analog
peptide (A9) with amino acid substitutions made at posi-
tions 260 (I to A), 261 (A to B), and 263 (F to N) that pro-
foundly suppressed immunity to CII and arthritis. In a
mouse model of RA, A9 protein therapy achieved a dra-
matic arrest in the overall disease progression as judged
by clinical, histopathological, and immunological mani-
festations of arthritis [8]. We now demonstrate in vivo
immunomodulatory properties of rCB11-A9, supporting
its therapeutic potential in the treatment of inflammatory
autoimmune disorders. Such collagen peptides contain-
ing specially designed substitutions and expressed as
gene products may provide an ideal choice to be delivered
to the joints. The advantages over conventional therapies
include the ease with which they can be injected at the
site of the inflammation, targeting the specific arthrito-
genic lymphocytes that initiate and perpetuate joint
inflammation, and transforming potential inflammatory
T cells and/or bystander T cells into therapeutic (regula-
tory-like) T cells. Our results suggest that the effects are
primarily localized to the joints, although we have not
performed biodistribution studies. They are potentially
safer than current therapies because they contain a modi-
fication of an endogenous naturally occurring protein.
The use of the gene therapy overcomes the problems of
rapid degradation and short half-life of small synthetic
proteins in vivo.
Another great advantage of gene delivery to the syn-
ovial cells is that they contain the enzymatic apparatus to
apply post-translational modifications, including the
hydroxylation and glycosylation of lysine residues, which
occur in chondrocyte synthesized CII, but not synthetic
peptides. It is known that CII peptide fragments derived
from the cyanogen bromide digestion of native CII are
immunologically more active than chemically synthe-
sized peptides [24,25]. It is now generally accepted that
part of the T cell response to cartilage-derived CII is
dependent upon the presence of glycosylated determi-
nants, which stabilize major histocompatibility complex/
Table 3: Cytokine responses in mice treated with gene therapy
Cytokines(pg/ml)
Treatment Antigen IL-2 IFN-γ IL-17 IL-4 IL-5 IL-10
AdenoX-Lac-z Ova 131 ± 12 137 ± 14 280 ± 22 1 ± 1 82 ± 10 18 ± 8
AdenoX-Lac-z Collagen peptide 1,405 ± 120 643 ± 25 6,364 ± 220 7 ± 3 762 ± 44 214 ± 17
AdenoX-Lac-z PPD 631 ± 50 2,451 ± 50 8,612 ± 267 3 ± 2 820 ± 63 262 ± 21
AdenoX-rCB11A9 Ova 120 ± 15 164 ± 22 250 ± 25 2 ± 1 75 ± 8 16 ± 9
AdenoX-rCB11A9 Collagen peptide 152 ± 14 143 ± 15 286 ± 25 44 ± 6 203 ± 21 47 ± 11
AdenoX
rCB11A9
PPD 776 ± 62 2,620 ± 232 8,633 ± 547 2 ± 2 778 ± 83 245 ± 26
Groups of three DBA/1 mice were administered intra-articularly either adenoX-rCB11-A9 or adenoX-LacZ and the mice were immunized with 
type II collagen/complete Freund's adjuvant (CII/CFA) three days after the injection. Draining lymph node cells were harvested 14 days after 
the immunization and cultured (5 × 106 cells/ml) with 100 μg/ml of the indicated antigens, either Ova (negative control), the mouse collagen 
immunodominant wild type peptide, or Purified Protein Derivative (PPD) (positive control). Supernatants were collected 72 hours later and 
analyzed for the presence of the indicated cytokines. Values are expressed as picograms per ml and represent the mean values for each group.
Cytokines IL-2, IFN-γ, IL-17, IL-5, and IL-10 were all significantly higher in response to the mouse collagen immunodominant peptide in the 
adenoX-lacZ treated mice compared with mice treated with adenoX-rCB11-A9 (P ≤ 0.05). On the other hand, IL-4 was significantly greater in 
the mice treated with aden-rCB11-A9 (P ≤ 0.05).
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Page 8 of 9T cell receptor (MHC/TCR) interaction or act as part of
the epitope [24-27].
Despite these advantages, it should be noted that there
is no consensus concerning the ideal vector for human
gene therapies. For example, patients can carry pre-exist-
ing neutralizing antibodies to adenoviral vectors or
develop them after the first injections, reducing their
effectiveness. Although scientific breakthroughs continue
to move gene therapy toward mainstream medicine,
future research should enhance clinical applications of a
collagen-based gene therapy for RA.
Conclusions
In summary, our studies demonstrate that: recombinant
CB11-A9 adenovirus can efficiently transfer and express
exogenes in joints and synovial tissue; the expression per-
sists for at least 18 days after the injection; and this type
of therapy is effective at both prevention and treatment of
autoimmune arthritis. These data strongly support our
hypothesis that adenoviral-mediated modified collagen-
type therapies can suppress arthritis and transform acti-
vated T cells and bystander T cells into therapeutic (regu-
latory-like) T cells. Gene therapy has emerged as an
effective and promising therapeutic strategy for RA [3].
To this end, local gene delivery can provide an alternative
approach to achieve high, long-term expression of biolog-
ics, optimizing the therapeutic efficacy and minimizing
systemic exposure. Future analogs can be optimized for
binding to the human MHC [28]. Our data using adenoX-
rCB11-A9 in the CIA animal model convincingly sup-
ports the possibility of a collagen-based gene therapy for
RA.
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